OpenLB
Open Library of Bioscience
Advanced Search
British journal of haematology
07, 2020;190 (2): e110-e114.

Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.

Eliza M Lauer, Miguel Waterhouse, Moritz Braig, Jurik Mutter, Sabine Bleul, Jesús Duque-Afonso, Justus Duyster, Reinhard Marks, Peter C Reinacher, Marco Prinz, Gerald Illerhaus, Jürgen Finke, Elisabeth Schorb, Florian Scherer
Author Information
  1. Eliza M Lauer: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  2. Miguel Waterhouse: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  3. Moritz Braig: Department of Radiology, Medical Physics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  4. Jurik Mutter: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  5. Sabine Bleul: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  6. Jesús Duque-Afonso: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  7. Justus Duyster: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  8. Reinhard Marks: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  9. Peter C Reinacher: Department of Stereotactic and Functional Neurosurgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  10. Marco Prinz: Institute of Neuropathology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  11. Gerald Illerhaus: Department of Hematology/Oncology and Palliative Care, Stuttgart, Germany.
  12. Jürgen Finke: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  13. Elisabeth Schorb: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ORCID
  14. Florian Scherer: Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. ORCID
PMID: 32452526 DOI: 10.1111/bjh.16759

Abstract

No abstract text available.

Keywords

BTK inhibition Ibrutinib central nervous system lymphoma real-world analysis relapsed/refractory disease

References

  1. Langner-Lemercier S, Houillier C, Soussain C, Ghesquieres H, Chinot O, Taillandier L, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18:1297-303.
  2. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869-81.
  3. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922-6.
  4. Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, et al. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: a retrospective case series. Neurology. 2017;88:101-2.
  5. Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2019;133:436-45.
  6. Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(833-843):e5.
  7. Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121-30.
  8. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-43.
  9. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82.
  10. Grommes C, Younes A. Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. Cancer Cell. 2017;31:731-3.

Grants

  1. /Deutsche Gesellschaft für Innere Medizin
  2. /Fördergesellschaft Forschung Tumorbiologie

MeSH Term

Adenine
Aged
Aged, 80 and over
Central Nervous System Neoplasms
Female
Humans
Lymphoma
Male
Middle Aged
Neoplasm Recurrence, Local
Piperidines
Retrospective Studies

Chemicals

Piperidines
ibrutinib
Adenine
Letter Research Support, Non-U.S. Gov't
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0Ibrutinibrelapsed/refractorycentralnervoussystemanalysispatientslymphoma:retrospectivesingle-centreBTKinhibitionlymphomareal-worlddisease

Similar Articles

Cited By (10)